In This Article:
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.
Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.
Is This 1 Momentum Stock a Screaming Buy Right Now?
Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
Amicus Therapeutics (FOLD)
Based in Cranbury, NJ, Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in discovering, developing, and commercializing a diverse set of novel treatments for patients with rare metabolic diseases. The company has one marketed medicine in its portfolio, Galafold (migalastat), which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants.
FOLD sits at a Zacks Rank #1 (Strong Buy), holds a Momentum Style Score of B, and has a VGM Score of B. The stock is down 2.9% and up 10.6% over the past one-week and four-week period, respectively, and Amicus Therapeutics has lost 1.1% in the last one-year period as well. Additionally, an average of 2,700,832.75 shares were traded over the last 20 trading sessions.
Momentum investors also pay close attention to a company's earnings. For FOLD, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $0.22 per share for 2024. FOLD boasts an average earnings surprise of 27.1%.
Investors should take the time to consider FOLD for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report